TT Sep 2024 290.000 call
| Previous Close | 40.70 |
| Open | 47.28 |
| Bid | 45.60 |
| Ask | 48.20 |
| Strike | 290.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 40.55 - 47.80 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 56 |
ZacksAvis Budget (CAR) Gains 28% Despite Earnings Miss in Q1
Avis Budget (CAR) witnesses a y/y decline in revenues from the Americas, while international revenues increase.
ACCESSWIRETrane Technologies and the U.S. Department of Energy Partner To Advance Building Decarbonization in New Heat Pump Technology Challenge
Following its industry-leading performance in the DOE's Residential Cold Climate Heat Pump Challenge, company brings its expertise to commercial heat pump challenge SWORDS, IRELAND / ACCESSWIRE / May 8, 2024 / Trane Technologies (NYSE:TT), a global ...
PR NewswireAcepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).
